Skip to main content

NRG-BR008 HERO / CRBRS23022 / Gergelis

Basic Study Information

This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.

Location: Highland Hospital

Lead Researcher (Principal Investigator)

Lead Researcher:  Kimberly Gergelis

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email:

Additional Study Details

Return to Search